VI Technologies' Unattributed VC - II Round

VI Technologies raised a round of funding on December 19, 2003.

Vitex is developing products designed to improve the safety of the world's blood supply. The Company's proprietary INACTINE technology, currently in a Phase III clinical trial, is designed to inactiva…

Articles about VI Technologies' Unattributed VC - II Round: